Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
BEAM 
Beam Therapeutics Inc (BEAM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/07/2026: BEAM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $46.07
1 Year Target Price $46.07
| 10 | Strong Buy |
| 4 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -35.78% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/07/2026 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.88B USD | Price to earnings Ratio - | 1Y Target Price 46.07 |
Price to earnings Ratio - | 1Y Target Price 46.07 | ||
Volume (30-day avg) 17 | Beta 2.07 | 52 Weeks Range 13.53 - 35.25 | Updated Date 01/7/2026 |
52 Weeks Range 13.53 - 35.25 | Updated Date 01/7/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.41 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1307.6% |
Management Effectiveness
Return on Assets (TTM) -23.48% | Return on Equity (TTM) -47.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1800037496 | Price to Sales(TTM) 51.63 |
Enterprise Value 1800037496 | Price to Sales(TTM) 51.63 | ||
Enterprise Value to Revenue 32.32 | Enterprise Value to EBITDA -7.03 | Shares Outstanding 101474944 | Shares Floating 87405534 |
Shares Outstanding 101474944 | Shares Floating 87405534 | ||
Percent Insiders 1.19 | Percent Institutions 102.06 |
Upturn AI SWOT
Beam Therapeutics Inc
Company Overview
History and Background
Beam Therapeutics Inc. was founded in 2017 by Flagship Pioneering. The company is a biotechnology company focused on developing a new class of therapeutics called base editing, a novel gene editing technology. Key milestones include significant fundraising rounds, progression of its pipeline candidates into clinical trials, and advancements in its base editing technology platform.
Core Business Areas
- Base Editing Therapeutics: Developing novel gene editing therapies using its proprietary base editing technology to precisely correct genetic mutations that cause disease. This technology aims to edit DNA directly without making double-strand breaks, potentially leading to safer and more effective treatments.
- Preclinical Research and Development: Conducting extensive research to identify and validate new targets for base editing therapies across a range of genetic diseases, including hematological disorders, neurological disorders, and inherited liver diseases.
Leadership and Structure
Beam Therapeutics is led by a management team with extensive experience in biotechnology and drug development. The organizational structure is typical for a biotechnology company, with dedicated departments for research and development, clinical operations, regulatory affairs, manufacturing, and corporate functions.
Top Products and Market Share
Key Offerings
- BEAM-101: A base editing therapy candidate designed to treat severe sickle cell disease and beta-thalassemia by precisely editing the DNA to restore functional hemoglobin. Competitors include other gene therapy and gene editing companies developing treatments for these conditions, such as Vertex Pharmaceuticals (CTX001).
- BEAM-201: A base editing therapy candidate for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LL). Competitors include other CAR-T therapy developers and emerging gene editing companies targeting these hematological malignancies.
- BEAM-350: A base editing therapy candidate for the treatment of alpha-1 antitrypsin deficiency (AATD). Competitors include companies developing gene therapies or other novel approaches for AATD.
Market Dynamics
Industry Overview
The gene editing and gene therapy market is a rapidly evolving and highly innovative sector within the biotechnology industry. It is characterized by significant scientific advancements, substantial investment, and the potential for transformative treatments for previously intractable genetic diseases. Regulatory pathways are becoming more defined, but challenges remain in manufacturing, delivery, and long-term safety.
Positioning
Beam Therapeutics is positioned as a leader in the field of base editing, a distinct and potentially advantageous approach within the broader gene editing landscape. Its proprietary technology allows for precise, single-base edits without DNA double-strand breaks, aiming for a differentiated safety and efficacy profile. The company's focus on genetically defined diseases with high unmet medical needs provides a strong strategic advantage.
Total Addressable Market (TAM)
The TAM for gene editing and gene therapy is substantial and growing, encompassing numerous rare and common genetic diseases. While precise TAM figures vary by disease indication, the market for inherited blood disorders, neurological conditions, and liver diseases alone represents tens of billions of dollars. Beam Therapeutics is positioned to capture a significant portion of the TAM for diseases addressable by its base editing technology, particularly for conditions where precise genetic correction is paramount.
Upturn SWOT Analysis
Strengths
- Pioneering base editing technology with potential for precise gene correction.
- Strong intellectual property portfolio in base editing.
- Experienced leadership team with a track record in biotechnology.
- Strategic partnerships and collaborations to advance pipeline.
- Focus on well-defined genetic diseases with high unmet needs.
Weaknesses
- Early-stage company with most candidates in clinical development or preclinical.
- High R&D costs and long development timelines.
- Reliance on future successful clinical trial outcomes and regulatory approvals.
- Potential for off-target edits or unforeseen long-term effects of gene editing.
Opportunities
- Expansion of base editing technology to a wider range of genetic diseases.
- Potential for in vivo and ex vivo therapeutic applications.
- Advancements in delivery mechanisms for gene editing tools.
- Growing investor interest and funding in the gene editing space.
- Potential for strategic acquisitions or partnerships with larger pharmaceutical companies.
Threats
- Competition from other gene editing technologies (e.g., CRISPR-Cas9).
- Challenges in regulatory approval processes and evolving guidelines.
- Manufacturing scalability and cost challenges for gene therapies.
- Potential for unexpected safety issues during clinical trials.
- Intellectual property disputes and patent challenges.
Competitors and Market Share
Key Competitors
- CRISPR Therapeutics (CRSP)
- Intellia Therapeutics (NTLA)
- Editas Medicine (EDIT)
Competitive Landscape
Beam Therapeutics' primary advantage lies in its proprietary base editing technology, which offers a potentially more precise and safer approach than traditional gene editing methods like CRISPR-Cas9. However, it faces strong competition from companies with established CRISPR platforms and significant clinical development progress. The ability to demonstrate superior efficacy and safety profiles will be critical for Beam to capture market share.
Growth Trajectory and Initiatives
Historical Growth: Beam Therapeutics has experienced rapid growth since its inception, marked by significant advancements in its base editing platform, expansion of its pipeline, and successful capital raises. The company has progressively moved its lead candidates towards and into clinical trials.
Future Projections: Future growth is contingent on the successful development and commercialization of its pipeline candidates. Analyst projections typically focus on the potential market penetration and revenue generation once therapies gain regulatory approval. Growth will likely be driven by progress in clinical trials, expansion into new therapeutic areas, and potential strategic partnerships.
Recent Initiatives: Recent initiatives include advancing its lead programs into clinical trials, expanding its manufacturing capabilities, and forging strategic collaborations to accelerate drug development and broaden the application of its base editing technology.
Summary
Beam Therapeutics is a promising biotechnology company at the forefront of base editing technology. Its strengths lie in its innovative platform and experienced team, with significant opportunities in treating genetic diseases. However, the company faces challenges common to its sector, including high R&D costs, long development timelines, and intense competition. Careful navigation of clinical and regulatory hurdles, alongside continued technological advancement, will be crucial for its long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Investor Relations Websites
- Financial News Outlets (e.g., Bloomberg, Reuters, Wall Street Journal)
- Biotechnology Industry Analyst Reports
- Market Research Databases
Disclaimers:
This JSON output is generated based on publicly available information and is for informational purposes only. It does not constitute financial advice, investment recommendations, or a guarantee of future performance. Market share data is illustrative and may not reflect precise real-time figures. Investors should conduct their own due diligence and consult with qualified financial professionals before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Beam Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2020-02-06 | CEO & Director Mr. John M. Evans M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 510 | Website https://beamtx.com |
Full time employees 510 | Website https://beamtx.com | ||
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.